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Abstract: Following its validation and wide application in rheumatoid arthritis (RA), synovial tissue analysis has recently 
been applied to studies on Psoriatic Arthritis (PsA). Such studies aim to thereby clarify its distinctive features and the 
nature of specific responses upon administration of disease modifying anti-rheumatic drug (DMARD) or biologic agents. 
In consequence, insights to disease pathogenesis, drugs’ mechanisms of action (MOA) and biomarkers of response have 
emerged. Data from pilot and open-label studies, and recently from randomized controlled trials, have helped in refining 
the therapeutic approaches to PsA patients, by improving understanding of MOA and in provision of biomarkers of 
response. The availability of less invasive and reproducible analysis techniques to obtain and evaluate synovial biopsies 
will further enhance the utility of this approach in due course. 
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INTRODUCTION 
 Psoriatic arthritis (PsA) is a chronic inflammatory disease 
classified amongst spondyloarthropathies (SpA) and affecting 
patients with either concomitant cutaneous psoriasis or a 
personal or family history of the same [1]. Clinical presentation 
of PsA is heterogeneous, variably involving synovium of 
peripheral joints, spine and/or entheses [2]. Patients with PsA 
may develop articular structural damage both in terms of 
erosions and new bone formation, and may also develop 
systemic complications including the development of metabolic 
syndrome and increased cardiovascular risk with concomitant 
reduced life expectancy [3,4]. To avoid or at least reduce these 
complications and to improve patients’ quality of life, the 
application of an appropriate and prompt treatment approach is 
mandatory. Ideally such therapeutics would be targeted to those 
patients most likely to benefit and least likely to develop 
toxicity. The synovium in PsA represents a primary target of 
disease pathogenesis, together with the skin, thus it is an 
intriguing and plausible site at which to explore important 
mechanisms of disease. Accordingly, evaluation of synovial 
tissues may assist identification of a drug’s local mechanism(s) 
of action, the stratification of patients more likely to achieve a 
beneficial effect from a given therapy and the definition of new 
targets and their effectiveness [1,5]. With respect to the latter, it 
is conceivable that tissue changes early after an intervention 
may prove predictive of future efficacy and as such could 
improve early ‘go/no-go’ decision making in drug development, 
thereby limiting patient exposure to either placebo or ineffective 
therapies. 
SYNOVIAL TISSUE ANALYSIS IN PSA 
 The synovial membrane in PsA comprises a thickened 
lining layer containing fibroblast-like synoviocytes and  
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macrophages, overlying a deep interstitial inflammatory 
tissue within which are situated macrophages, T and B 
lymphocytes, NK cells, mast cells and widespread evidence 
of neovascularisation and to some extent lymphangiogenesis. 
In a substantial number of biopsies there are germinal centre-
like reactions at present of unclear pathologic consequence. 
The advent of TNF blocking therapeutics provides ample 
evidence of the potential utility of synovial tissue as a 
resource for choosing novel therapeutic targets. Recently, 
pioneering studies lead by Tak, Bresnihan and others in the 
RA field have lead to the suggestion that synovial tissue may 
also provide a resource for biomarkers with predictive utility 
[6]. Thereby, trials in which synovial tissue is obtained upon 
a given intervention offer the potential advantage of 
requiring smaller patient group sizes than conventional phase 
IIa and IIb trials, with shorter follow-up to pivotal decisions 
[7]. At a technical level, studies in PsA have largely taken 
advantage of the validation of methods performed in RA 
synovial tissue analysis, both for obtaining synovial biopsies 
and the methods employed to analyse them [7]. Additional 
studies have also been initiated in the group of 
spondyloarthropathies as a whole [8]. Thus, the same 
techniques (arthroscopic and US-guided biopsy) and 
methods for immunohistologic assessment (manual count, 
semi-quantitative scores and digital image analysis) and 
molecular gene analysis (PCR, microarrays) that have 
contributed to the current knowledge on the pathobiology of 
inflammatory arthritides have been readily transferred to 
PsA [7, 9]. It is likely but must yet to be proven that the 
methodologies so far employed in RA will be readily 
applicable to PsA analyses. It is less clear however whether 
the same cellular or protein biomarkers will prove useful: the 
underlying conditions are tangibly different and several 
recent studies point to unique features of synovial tissue 
structure and composition between diseases. In particular, 
immunopathogenic appearances reveal similarities between 
SpA subgroups, for example comparing oligo- or 
polyarticular PsA, in terms of major histologic parameters 
(including lining layer thickness, vascularity, PMN, CD68+ 
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and CD163+ lining and of sublining macrophages) [10]. This 
is also true when judged against their response to effective 
treatment [11]. Nevertheless subtle but potentially functional 
differences could be critical in allowing a more precise 
stratification and tailoring of drug to individual patients [12, 
13]. Furthermore, studies on the effect of interventions on 
PsA synovial tissue conducted thus far have been limited to 
small numbers of patients, incomplete evaluation of early 
and late follow-up time points and the lack of a specific 
measure of disease activity in PsA. This in turn reflects 
imperfect validation of the DAS28 and ACR response 
criteria in clinical trials of PsA [14]. These issues might have 
affected the specificity of the results and further 
investigations should be encouraged. 
 Nevertheless, available data on the local synovial effect 
of different classes of drugs in PsA have provided insights 
on the mechanism of action of conventional DMARDs and 
new biological agents, contributing to effective improvement 
of clinical practice and understanding of PsA synovial 
pathobiology. We summarise such data below (see also 
Table 1). 
DMARDs - EFFECT ON SYNOVIAL TISSUE 
 Various DMARDs including sulphasalazine, leflunomide 
and methotrexate (MTX) are widely used in general clinical 
practice to treat PsA. There remains however a rather sparse 
placebo-controlled literature that supports their efficacy in 
terms of ameliorating signs and symptoms and structural 
progression [1]. Studies demonstrating the synovial effect of 
such drugs are particularly scarce. Most evidence comes 
from patients treated with MTX. Its effect was evaluated on 
the synovial leukocyte infiltrate and mRNA and protein 
levels of several T cell- and macrophage-derived cytokines 
in a study of a small group of PsA patients [15]. Synovial 
biopsies were taken before MTX initiation and at various 
follow-up time-points (6-18 months). All patients showed a 
clinically significant improvement by means of Ritchie 
articular index (RAI), swollen joint count and disease 
activity score (DAS). The synovial changes paralleling this 
response showed reduced expression of CD3, CD4, CD8 and 
CD68 in the sublining area as well as a reduction in the 
thickness of the lining layer. Analogously to what happens 
in RA synovitis [16], the change in CD68+ cell sublining 
infiltration correlated strongly and significantly with 
parameters of systemic inflammation such as ESR. An 
additional effect of MTX was to significantly reduce the 
expression of adhesion molecules such as VCAM, ICAM 
and E-selectin on sublining area vessels. 
 The immunobiology of PsA synovitis and its 
modifications after MTX were also investigated by a 
comparative analysis of the T cell receptor (TCR) repertoire 
in synovial tissue biopsies and paired synovial fluid (SF) and 
peripheral blood (PB) [17]. This analysis revealed that an 
effective response, again determined by a significant 
improvement in RAI, swollen joint count and DAS, was 
mirrored by a substantial decrease in the polyclonal 
component of the synovial T cell infiltrate, representing in 
turn a major component of the inflammatory infiltrate. A 
smaller decrease was also detected in the oligoclonal T cell 
populations. Most of the TCR clones that were exclusively 
found in the inflamed tissue did not survive after treatment 
while a small subset of clones could be persistently detected 
in the tissue. The latter also showed clonal expansion in 
other compartments such as SF and PB. These cells were 
identified by transcripts of the CD8 lineage. Their high 
homology suggested a possible antigen-driven process, 
commensurate with previous results obtained by clonal 
analysis of TCR in isolated lymphocytes from actively 
inflamed PsA SF [18]. The differential modulation of an 
effective therapy might suggest different functions for these 
clones, the MTX-responsive being inflammation-related and 
the MTX-resistant having a more consistent role in 
pathogenetic mechanisms. Indeed, despite the small number 
of patients included and the pragmatic definition of efficacy 
(no formal ACR or EULAR response core sets are given in 
both studies and MTX effect is evaluated at different follow-
up time points), these results provide compelling evidence 
that MTX directly modulates the inflammatory infiltrate in 
PsA. Moreover they point to a major contribution of T cells, 
and the CD8 subset in particular, to PsA pathogenesis and 
chronicity. 
Table 1. Local Synovial Effect Induced in PsA Clinical Trials 
 





Reduction of synovial layer thickness 
Reduction of CD3, CD4, CD8, CD68 sublining 
infiltration 
Reduction of polyclonal, inflammation-related CD4+ T 
cells, smaller effect on oligoclonal CD8 T cells 
[15, 17] 
Infliximab TNF 
Reduction of synovial layer thickness 
Reduction of vascularity and endothelial cell activation 
[22-24, 26,28] 
Adalimumab TNF 
Reduction of the synovial layer thickness 
Reduction of CD3 infiltration 
Reduction of MMP-13 expression 
[27] 
Etanercept TNF, lymphotoxin 
Reduction of the synovial layer thickness 
Reduction of CD68+ and CD163+ macrophages 
Reduction of MMP-3 and MMP-9 
[11] 
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 To assess the potential beneficial effect of a lymphocyte-
depleting drug, a study of the synovial infiltrate in PsA 
patients treated with the fludarabine was performed [19]. 
PsA patients responded only modestly to fludarabine after 16 
weeks of treatment, and did not perform significantly better 
than placebo when ACR20 response were calculated. This 
was reflected by a limited effect on infiltrating T 
lymphocytes and E-selectin endothelial expression. 
Furthermore, no changes in the CD14+ component of the 
synovial inflammatory cells or on P-selectin could be 
detected. This stable presence of infiltrating macrophages 
and the persistence of a memory T cell subset that was 
presumably resistant to depletion (reflected also by the 
increased memory/naïve T cell ratio in PB), provide indirect 
supportive evidence for the concept, also proven for RA 
[20], that local biomarkers may assist in the evaluation of a 
therapeutic regimen, even in small groups of patients. 
Accordingly, results from cross-sectional studies show that 
when a conventional treatment (e.g. with MTX) fails to 
achieve an adequate response in PsA patients that show 
active disease despite treatment, features of synovitis are not 
significantly different when compared to patients who do not 
receive any therapy [10], and the lack of response is reflected 
by persistence of inflammation [21]. 
BIOLOGICAL AGENTS - EFFECT ON SYNOVIAL 
TISSUE 
 The advent of biological therapies has had a significant 
impact on the treatment strategies whereby PsA is managed. 
TNF-alpha inhibitors have proven efficacious in PsA in 
reducing signs and symptoms of synovitis, improving 
patient-reported outcomes (Health Assessment 
Questionnaire, physical function, Quality of Life, and 
fatigue) and suppressing radiographic progression [1]. 
Synovial tissue analysis before and after anti-TNF-alpha 
therapy provides direct proof of their local efficacy and by 
inference their mode of action [5]. A further rationale to 
multiple and serial sampling of the PsA synovial tissue has 
been to obtain reliable biomarkers to be applied in the 
assessment of the newly developed agents. Several open-
label trials have clearly provided evidence for cellular and 
angiogenic changes in both PsA and other SpA subsets [22-
24]. In particular, evidence from these analyses provides 
concordant results. In PsA synovium, as previously indicated 
in RA [25], TNF blockade significantly reduces infiltration 
of sublining CD68+ macrophages and CD3+ T lymphocytes 
within 48 hours, and the effect is not achieved by influencing 
apoptotic homeostasis in the synovium, assessed by TUNEL 
and caspase-3 analysis [26]. A likely mechanism of action 
therefore is via “deactivation” of the endothelium [23]. 
Indeed, although the effect on the endothelium was not 
evaluated at the same very early time-point, after 4 weeks of 
therapy with low-dose infliximab, a significant reduction in 
the expression of ICAM-1 on synovial capillaries could be 
observed, with VCAM and E-selectin showing the same 
trend [23]. In parallel, the same study showed that 
vascularity itself was decreased and that synovial expression 
of pro-angiogenic factors, such as von Willebrand factor and 
VEGF, and of markers of neovascularization, namely ?v?3-
integrin, were down-regulated. Similarly, in a distinct trial of 
PsA patients treated with infliximab, significant reduction in 
CD68+ lining and sublining macrophages was observed after 
8 weeks [24]. In parallel, a decrease in vascularity was 
observed, that was mainly explained by a lower proportion 
of ?v?3-integrin neovessels in treated patients and 
accompanied by histologic and molecular down-modulation 
of VEGF and its receptors, VEGFR-1 and -2. Moreover, the 
chemokine SDF-1 showed significantly reduced vascular 
expression [24]. 
 Recently, a randomized, double blind, placebo-controlled 
trial with adalimumab has confirmed and reinforced previous 
results in open-label and smaller trials by comparing 
synovial tissue histology before and after a short course of 
treatment [27]. In this study, clinical efficacy assessed by 
DAS28, EULAR and ACR responses, was paralleled by a 
significant reduction of infiltrating CD3+ T lymphocytes, 
with CD68+ and CD163+, lining and sublining, total and 
resident macrophages also showing a reducing trend. A 
marked reduction in MMP-3 and MMP-13 expression after 
treatment was also demonstrated. By covariance analysis of 
all the tested variables, and thus taking into account the 
inter-patient variability and baseline differences already 
present despite randomization, the decrease in CD3+ T cell 
infiltration and in MMP-13 expression still significantly 
reflected changes induced by the TNF-alpha inhibitor. These 
results again point out the importance of T cells in PsA 
pathobiology and suggest CD3+ cells and MMP-13 as 
synovial biomarkers of response to effective treatments. 
 TNF blockade may also influence the presence of ectopic 
lymphoid aggregates that resemble secondary lymphoid 
organs (lymphoneogenetic (LN) structures), occurring in RA 
and recently described also in PsA [28]. A histologic 
analysis showed persistence of LN features over the course 
of TNF-alpha blockade in non-responders patients and their 
regression in those undergoing clinical remission. Although 
the small numbers recruited and the preliminary nature of 
this study preclude definitive conclusion, in light of recent 
data in RA showing a reversal of LN in patients who 
achieved a good EULAR response after a short course of 
anti-TNF-alpha therapy [29], LN features could represent a 
valuable biomarker of response and deserve further analysis 
in PsA. 
 Tissue biomarkers and their modification following 
additional immuno-modulatory treatments have been 
explored in other trials. Thus, after administration of 
recombinant IL-10 in PsA patients [30], in a study designed 
to assess safety and tolerability of the drug (not powered to 
detect a significant clinical effect of the drug on articular 
disease) the synovial tissue showed a significant reduction in 
CD3+ T lymphocytes and CD68+ lining and sublining 
macrophages, together with a decreased proportion of P-
selectin+ vessels and a down-regulation of vascular ?v?3-
integrin [30]. Similarly, the effect of alefacept, a 
recombinant protein that blocks the interaction between 
LFA3 and CD2 and subsequently inhibits T cell activation 
and proliferation, has been evaluated in PsA synovium in a 
small open-label trial [31]. Alefacept induced a local 
significant reduction of effector T cells and of sublining 
macrophages, with a pronounced response, in the CD45RO+ 
T lymphocyte memory subset. More recently, the synovial 
tissue response to abatacept, a CTLA4-Ig fusion protein, has 
been also described in a case report of a patient with severe 
refractory PsA [32]. Interference with co-stimulatory 
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pathways was efficacious in terms of clinical parameters of 
the patient joint and skin disease and in inducing reduction 
of synovial infiltration of CD15+ lining neutrophils, CD68+ 
sublining macrophages and CD3+ T lymphocytes. 
DIFFERENTIAL RESPONSE TO THERAPY OF 
SYNOVIUM AND SKIN 
 The presence of a simultaneous cutaneous and articular 
disease and the relative ease of access to both target sites 
make it possible to compare the local effect of drugs in 
different tissue compartments. Cutaneous psoriatic lesions 
are characterized by keratinocyte proliferation, an 
inflammatory infiltrate driven by a cytokine and chemokine 
network and endothelial activation with enhanced adhesion 
molecule and integrin expression [33]. Despite differences in 
embryonic origin, the resident cellular components of the 
two tissues and the pathological lesions share common 
features, cytokine expression patterns and TCR oligoclonal 
expansion [34]. Moreover, strong similarities can be derived 
from the mechanisms of action and local effect of the same 
drugs. Indeed, immune modulation by use of conventional 
agents (for example MTX, cyclosporine) and of the more 
recent biologic agents (anti-TNF alpha agents primarily) has 
proven efficacious in psoriasis as in PsA by means of 
reduced vascularity, endothelial cells activation and 
inflammatory cell infiltration [23]. Nonetheless, studies 
directly comparing effects of drugs on both tissues have 
occasionally revealed discrepancy between skin and 
synovium responses, especially when the efficacy of the 
drug was limited overall or the dosage of the drug was 
suboptimal for one compartment [19, 23, 30]. These 
differential responses and their biological basis have not 
been clarified as yet and require further investigation. Beside 
pharmacokinetic explanations, biologic mechanisms for 
discrepant responses have been proposed. For example 
apoptosis of dermal CD11c+ DCs can be induced by TNF-
alpha blockade in psoriatic skin responsive to treatment [35]. 
The same effect has not been documented in the synovium, 
where apoptosis is not thought to be a major contributor to 
the reduction of the inflammatory infiltrate [25] and where 
understanding the functional importance of the different DC 
subsets remains controversial [36-38]. A reduction in PB 
levels of DCs, and plasmacytoid DCs (pDCs) in particular, 
has been demonstrated along with their selective 
accumulation in inflamed peripheral tissues [36]. It has also 
been recently suggested that pDCs might exert local anti-
inflammatory activities, since their depletion was detrimental 
in a model of experimental arthritis [38]. Case reports have 
accordingly shown an increase in circulating pDCs following 
an effective DMARDs combination therapy [39], but data so 
far are limited and deserve further elucidation. Indeed, 
specifically investigating the role of effective therapies in 
modulating DCs, their different phenotypes, maturation 
states and circulating pathways will provide a valuable 
insight into how skin and articular lesions are 
interconnected. 
CONCLUDING REMARKS 
 The ability to perform short-term early phase clinical 
trials has become crucial in the last few years because of the 
increasing numbers of drugs developed to treat inflammatory 
arthritides, including PsA, in a more aggressive, specific and 
efficient way. The analysis of synovial tissue has rendered 
such studies feasible. The validation of minimally invasive 
and repeatable techniques for synovial tissue biopsy has 
provided a direct insight into the tissue target of the disease. 
This pertains to understanding pathogenic mechanisms and 
to the development of sensitive biomarkers of response. 
Future studies in PsA are now required to complement the 
growing evidence base in RA and maximise the yield from 
this new investigative approach. 
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